TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05324813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domain-Specific Episodic Future Thinking
Description: Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Domain-Specific Episodic Future Thinking
Description: Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
Study: NCT05203224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: Intravenous Dornase alfa
Study: NCT05610059

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure Technology System M
Description: Participants will be provided the blood pressure technology system M. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Pressure Technology System E
Description: Participants will be provided the blood pressure technology system E. The study staff will teach the participants how to use the system on their personal cell phones with instruction guides. Participants will be asked to use the system for 6-months.
Study: NCT06043453

Intervention type: OTHER
Intervention: revitalization
Description: The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
Study: NCT05899647

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultraviolet Microscopic Analysis
Description: Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected.
Study: NCT05629091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibDex
Description: Nanofibrillar cellulose wound dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epicite hydro
Description: Wound dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epiprotect
Description: Wound dressing
Study: NCT06181786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-101
Description: Intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-101
Description: Intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching-placebo intravenous administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching-placebo intravenous administration.
Study: NCT04747873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Description: Stepped care procedure (see arm/group descriptions).
Study: NCT04825496

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ssCART-19 Cells
Description: Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study: NCT04768868

Intervention type: DRUG
Group type: OTHER
Intervention: IMP7068
Description: To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
Study: NCT04825496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT06133413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Comp Pro connected scale (Withings manufacturer)
Description: Use once a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert generation by remote plateform
Description: Alert will be generated from weight regain \> 5% of baseline weight
Study: NCT06345898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWK002
Description: Subretinal administration of gene therapy vector JWK002 to one eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWK002
Description: Subretinal administration of gene therapy vector JWK002 to one eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWK002
Description: Subretinal administration of gene therapy vector JWK002 to one eye.
Study: NCT05546424

Intervention type: BEHAVIORAL
Intervention: EMRESERVA
Description: training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.

Intervention type: BEHAVIORAL
Intervention: EMRESERVA
Description: training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
Study: NCT05147649

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional magnetic resonance imaging
Description: functional magnetic resonance imaging
Study: NCT05321771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family caregiver application of HELP principles
Description: The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
Study: NCT05573347

Intervention type: PROCEDURE
Intervention: Rotator Cuff Repair
Description: Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
Study: NCT05289024

Intervention type: BEHAVIORAL
Intervention: Mindful Awareness in Body-Oriented Therapy
Description: Up to 8 individually delivered clinical sessions
Study: NCT05695105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush-Generated Vibration
Description: Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
Study: NCT05573347

Intervention type: PROCEDURE
Intervention: Rotator Cuff Repair
Description: Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)

Intervention type: PROCEDURE
Intervention: Bone Marrow Harvest
Description: Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body

Intervention type: PROCEDURE
Intervention: Bone Marrow Harvest
Description: Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
Study: NCT04728932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: A continuous infusion of Levosimendan over 24h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Levosimendan
Description: A continuous infusion of Placebo of Levosimendan over 24h
Study: NCT03616236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Description: Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will receive a referral to buprenorphine treatment in the community
Study: NCT05695105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Toothbrush-Generated Vibration
Description: Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-Implant-Assisted Orthodontic Treatment
Description: Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
Study: NCT06022354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0278 Injection/Placebo
Description: SIM0278 Injection/Placebo
Study: NCT06534385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air purifier
Description: Winix HEPA air purifier
Study: NCT05646758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2934 injection
Description: TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
Study: NCT05627726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PelviSense-assisted pelvic floor muscle training group
Description: The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
Study: NCT05437237

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG
Description: A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
Study: NCT06234111

Intervention type: COMBINATION_PRODUCT
Intervention: Semaglutide 2.4 mg, total diet replacement, behavioural intervention
Description: Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
Study: NCT06509893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin 80 mg and clopidogrel 75 mg daily
Description: post PCI patients received these two drugs as dual antiplatelet regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 MG
Description: Post PCI patients receive Ticagrelor 90 mg two times daily as single potent antiplatelet
Study: NCT04280458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intentive rehabilitation
Description: Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months.
Study: NCT06237816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education Intervention
Description: Multimedia Educational Videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Education Intervention
Description: Provider workshops via zoom
Study: NCT05480865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: sotorasib administered orally
Study: NCT03438526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin (Circadin ®)
Description: 4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
Study: NCT06529354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity Group
Description: In water aerobics sessions, the exercises are performed at a moderate intensity, between 60% and 70% of the participant's maximum heart rate predicted by their age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Group
Description: In water aerobics sessions, the exercises are performed at a high intensity, between 80% and 90% of the participant's maximum heart rate predicted by their age.
Study: NCT04570345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor monotherapy
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor monotherapy
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin with P2Y12 receptor inhibitor
Description: • Drug: aspirin plus ticagrelor dual therapy during 12 months
Study: NCT03438526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
Study: NCT04786093

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy
Description: Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiation therapy
Description: Radiation therapy will be delivered using standard SAbR treatment schedule or every 4 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of durvalumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
Study: NCT05524480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salud en Mis Manos - Dissemination and Implementation Assistance
Description: The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Salud en Mis Manos- Usual Implementation Practice
Description: The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
Study: NCT06535633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention arm: Exercise class
Description: The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
Study: NCT05890430

Intervention type: BIOLOGICAL
Intervention: Blood draw, Urine draw
Description: Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time

Intervention type: BIOLOGICAL
Intervention: Blood draw, Urine draw
Description: Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time